Abstract
The dCTP pyrophosphatase 1 (dCTPase) is a nucleotide pool “housekeeping” enzyme responsible for the catabolism of canonical and noncanonical nucleoside triphosphates (dNTPs) and has been associated with cancer progression and cancer cell stemness. We have identified a series of piperazin-1-ylpyridazines as a new class of potent dCTPase inhibitors. Lead compounds increase dCTPase thermal and protease stability, display outstanding selectivity over related enzymes and synergize with a cytidine analogue against leukemic cells. This new class of dCTPase inhibitors lays the first stone toward the development of drug-like probes for the dCTPase enzyme.
Funding Information
  • Vetenskapsr?det
  • G?ran Gustafssons Stiftelse f?r Naturvetenskaplig och Medicinsk Forskning
  • Knut och Alice Wallenbergs Stiftelse
  • Torsten S?derbergs Stiftelse
  • Cancerfonden
  • H2020 European Research Council
  • Swedish Children?s Cancer Foundation
  • Felix Mindus bidrag till leukemiforskningen
  • Swedish Pain Relief Foundation

This publication has 25 references indexed in Scilit: